Get the Stockscreener App
16.91
0.06%
0.01
Kalvista Pharmaceuticals Inc stock is traded at $16.91, with a volume of 597.03K.
It is up +0.06% in the last 24 hours and up +26.76% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$16.90
Open:
$16.84
24h Volume:
597.03K
Relative Volume:
0.42
Market Cap:
$854.74M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-4.5827
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
+2.92%
1M Performance:
+26.76%
6M Performance:
+29.18%
1Y Performance:
+93.37%
1-Day Range:
$16.40
$17.15
1-Week Range:
$15.88
$17.15
52-Week Range:
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
16.91 | 854.23M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
Stempoint Capital LP Cuts Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Discipline and Rules-Based Execution in KALV Response - news.stocktradersdaily.com
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $120,423.94 in Stock - MarketBeat
Possible Bearish Signals With KalVista Pharmaceuticals Insiders Disposing Stock - simplywall.st
Pharvaris surges, pulling KalVista out of a slump, on promising new HAE treatment - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Receives Buy Rating from Needham & Company LLC - MarketBeat
KalVista Pharmaceuticals, Inc. $KALV Shares Purchased by Stonepine Capital Management LLC - MarketBeat
Saturn V Capital Management LP Sells 192,267 Shares of KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Schroder Investment Management Group Has $6.27 Million Stock Holdings in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals Executive Sells Shares to Cover Tax Obligations - TradingView
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 15%Here's What Happened - MarketBeat
Panagora Asset Management Inc. Grows Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals (KALV) Rating Reiterated by Needham | K - GuruFocus
Needham reiterates KalVista Pharmaceuticals (KALV) buy recommendation - MSN
KalVista Pharmaceuticals (KALV) to Release Quarterly Earnings on Thursday - MarketBeat
Pharvaris’s Phase III HAE Data Position Deucrictibant For 2026 NDA Filing - Citeline News & Insights
Kalvista stock price target maintained at $30 by TD Cowen amid competitor data - Investing.com Nigeria
Biotechs Duke It Out In A Genetic Disease — And Both Surge - Investor's Business Daily
Pharvaris’ oral deucrictibant hits endpoints in acute HAE trial - BioWorld MedTech
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Sahm
Why pension funds invest in KalVista Pharmaceuticals Inc. (4XC1) stockWeekly Profit Analysis & High Conviction Buy Zone Alerts - Newser
Will KalVista Pharmaceuticals Inc. (4XC1) stock profit from automation waveJuly 2025 Review & Safe Capital Investment Plans - Newser
KalVista Pharmaceuticals (KALV) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How KalVista Pharmaceuticals Inc. stock reacts to inflationary pressures2025 EndofYear Setup & Free High Return Stock Watch Alerts - Newser
Is KalVista Pharmaceuticals Inc. stock a contrarian buyJuly 2025 Price Swings & Verified Momentum Stock Alerts - Newser
KalVista Pharmaceuticals, Inc. $KALV Stake Boosted by F m Investments LLC - MarketBeat
Behavioral Patterns of KALV and Institutional Flows - news.stocktradersdaily.com
KalVista Pharma exec Yea sells $58k in shares By Investing.com - Investing.com Australia
KalVista Pharma CMO Audhya sells $71k in stock By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Stock (KALV) Opinions on Q3 Revenue Success - Quiver Quantitative
KALV SEC FilingsKalvista Pharm 10-K, 10-Q, 8-K Forms - Stock Titan
KalVista Pharma CFO Piekos sells $60k in shares By Investing.com - Investing.com Canada
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CFO Sells 4,471 Shares of Stock - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
KalVista Pharma CMO Audhya sells $71k in stock - Investing.com
KalVista Pharma exec Yea sells $58k in shares - Investing.com
KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Officer Audhya Acquires 5,954 Of KalVista Pharmaceuticals Inc [KALV] - TradingView
KalVista Pharmaceuticals, Inc. (KALV) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is KalVista Pharmaceuticals Inc. stock positioned well for digital economyGap Down & High Conviction Buy Zone Picks - newser.com
Real time scanner hits for KalVista Pharmaceuticals Inc. explainedQuarterly Earnings Summary & AI Powered Buy and Sell Recommendations - newser.com
KalVista Pharmaceuticals officer fully exercises 87,390 share option grant - Stock Titan
Multi asset correlation models including KalVista Pharmaceuticals Inc.July 2025 Trends & Consistent Profit Trade Alerts - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth funds2025 Earnings Surprises & Stock Portfolio Risk Control - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock keep high P E multiplesQuarterly Portfolio Review & Consistent Growth Equity Picks - newser.com
Citizens reiterates Market Outperform rating on Kalvista stock at $28 target - Investing.com Canada
How to manage a losing position in KalVista Pharmaceuticals Inc.Watch List & Fast Gaining Stock Strategy Reports - newser.com
What market sentiment indicators show for KalVista Pharmaceuticals Inc. (4XC1) stockQuarterly Investment Review & Low Drawdown Momentum Ideas - newser.com
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):